B-ALL cell lines (NALM6 and RS4;11) and NALM6 phospho-GR mutants (GR-S203A and GR-S226A) were tested with combinations of prednisolone (Acros Organics, ThermoFisher, Waltham, MA, USA, #449470250) and the PI3Kδ inhibitor idelalisib (Gilead Sciences, Foster City, CA, USA). Viability was measured using PrestoBlue (ThermoFisher, Waltham, MA, USA, A13262). Synergy was evaluated using the Bliss synergy model in SynergyFinder 2.0 [19 (link)].
Primary specimens from children with newly diagnosed or relapsed B-ALL were obtained prior to initiating treatment after receiving informed consent (University of Iowa IRB protocol #201707711). Cells were obtained from either peripheral blood or bone marrow and isolated by Histopaque density gradient separation. Freshly isolated cells were used for all experiments involving primary specimens.
NALM6, SUP-B15, and RCH-ACV cells were tested with dexamethasone (Sigma-Alrich, St. Louis, MO, USA, D4902-1g) in combination with ERK1/2 inhibitor SCH772984 (SelleckChem, Houston, TX, USA, #S7101).
Primary specimens from children with newly diagnosed or relapsed B-ALL were obtained prior to initiating treatment after receiving informed consent (University of Iowa IRB protocol #201707711). Cells were obtained from either peripheral blood or bone marrow and isolated by Histopaque density gradient separation. Freshly isolated cells were used for all experiments involving primary specimens.
NALM6, SUP-B15, and RCH-ACV cells were tested with dexamethasone (Sigma-Alrich, St. Louis, MO, USA, D4902-1g) in combination with ERK1/2 inhibitor SCH772984 (SelleckChem, Houston, TX, USA, #S7101).
Free full text: Click here
